HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients by Margaret R. Dunne et al.
Vol.:(0123456789) 
Cancer Immunol Immunother 
DOI 10.1007/s00262-017-1983-1
ORIGINAL ARTICLE
HLA-DR expression in tumor epithelium is an independent 
prognostic indicator in esophageal adenocarcinoma patients
Margaret R. Dunne1 · Adriana J. Michielsen1 · Katie E. O’Sullivan1 · Mary Clare Cathcart1 · Ronan Feighery1 · 
Brendan Doyle2,3 · Jenny A. Watson3 · Naoimh J. O’Farrell1 · Narayanasamy Ravi1 · Elaine Kay3 · 
John V. Reynolds1 · Elizabeth J. Ryan4 · Jacintha O’Sullivan1 
Received: 7 December 2016 / Accepted: 4 March 2017 
© The Author(s) 2017. This article is an open access publication
tumor epithelium had significantly worse survival out-
comes, compared to those with high expression, in both 
the tumor core (hazard ratio, HR = 2.178, p = 0.024, n = 70) 
and leading edge (HR = 2.86, p = 0.013, n = 41). Multivari-
ate analysis demonstrated that low HLA-DR expression in 
leading edge tumor epithelium was an independent predic-
tor of poor survival, associated with a 2.8-fold increase 
in disease-associated death (p = 0.023). This study shows 
that HLA-DR is an independent prognostic marker in EAC 
tumor epithelium. This may have implications for patient 
stratification strategies as well as EAC tumor immunology.
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Abbreviations
BE  Barrett’s esophagus
CI  Confidence interval
DAB  Diaminobenzidine
EAC  Esophageal adenocarcinoma
GERD  Gastro-esophageal reflux disease
HGD  High-grade dysplasia
HR  Hazard ratio
LGD  Low-grade dysplasia
pN  Pathological lymph node stage
pT  Pathological tumour stage
TMA  Tissue microarrays
Introduction
Esophageal adenocarcinoma (EAC) is an aggressive malig-
nancy with poor prognosis and a 5-year survival of <15% 
[1]. Incidence is increasing in parallel with the growing 
Abstract Esophageal adenocarcinoma (EAC) is an 
aggressive cancer with poor prognosis, and incidence is 
increasing rapidly in the Western world. Measurement of 
immune markers has been shown to have prognostic sig-
nificance in a growing number of cancers, but whether this 
is true for EAC has yet to be evaluated. This study aimed to 
characterize HLA-DR expression in the esophagus across 
the inflammation to cancer progression sequence and to 
assess the prognostic significance of HLA-DR expression 
in EAC. Tissue microarrays (TMA) were constructed from 
esophageal tissue taken from patients at different stages 
in the cancer progression sequence; normal, esophagitis, 
Barrett’s esophagus (BE), low- and high-grade dysplasia 
(LGD, HGD) and EAC. HLA-DR expression in tissue epi-
thelium and stroma was assessed by immunohistochemis-
try. HLA-DR expression increased early in the inflamma-
tion to cancer progression sequence; with higher expression 
detected in esophagitis and BE compared to normal tissue. 
Patients with low (<50%) HLA-DR expression in the EAC 
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obesity epidemic [2] and the number of cases in Ireland is 
predicted to double by 2035 [3]. EAC is an inflammation-
driven cancer, as evidenced by the increased incidence 
observed in patients with the reflux-associated disorder 
Barrett’s esophagus (BE) [4]. BE is an inflammatory condi-
tion, which arises as a result of chronic gastro-esophageal 
reflux disease (GERD). BE is characterized by intestinal 
metaplasia, whereby squamous epithelium is replaced by 
columnar epithelial cells. Patients with BE are enrolled 
on endoscopic surveillance programs to monitor for early 
signs of dysplasia and prevent cancer development. Once 
EAC is established, treatment protocols increasingly utilize 
multi-modal approaches, where either neoadjuvant chemo-
therapy alone or combination chemoradiotherapy followed 
by surgical intervention has become the standard of care. 
However only 20–30% of patients will experience a com-
plete or partial response to such treatments [5, 6]. The 
clinical challenge in this area is the identification of factors 
or events which can predict patient clinical outcomes. In 
recent years, the infiltrating immune component of tumors 
has been shown to be an important factor in predicting 
patient clinical outcomes [7–10]. This has been demon-
strated for several cancer types, with a greater amount of 
infiltrating immune cells being associated with improved 
patient survival and reduced tumor reoccurrence.
In this study, we examined the role of the antigen-pre-
senting molecule human leukocyte antigen (HLA)-DR in 
EAC development. HLA-DR is part of the major histocom-
patibility complex (MHC) class II family of antigen presen-
tation molecules, encoded on human chromosome 6, region 
6p21.31. HLA-DR is constitutively expressed on antigen-
presenting cells such as dendritic cells, monocytes, B cells 
and activated T cells, but expression can also be induced 
in other cell types, including tumor cells, particularly in 
response to inflammatory conditions [11–13]. HLA-DR 
expression in tumors has been shown to be positively asso-
ciated with patient prognosis in some cancers [14, 15], such 
as colorectal cancer [16–18], gastric cancer [19], squamous 
cell carcinoma of the larynx [20], but is negatively associ-
ated with prognosis in other cancer types, such as glioma 
[21] and esophageal squamous cell carcinoma [22]. The 
reason for this discrepancy is unclear, although different 
groups use different scoring criteria, and tissue-specific dif-
ferences in HLA-DR expression have also been reported 
[23].
HLA-DR expression in tumors correlates with the pres-
ence of immune cells such as  CD16+ myeloid cells and T 
cells [16], and is, therefore, thought to reflect an immuno-
genic tumor microenvironment, capable of supporting an 
anti-tumor immune response. Indeed, MHC class II mol-
ecules such as HLA-DR are crucial to the development 
of CD4 T helper cell subsets [24]. However, it is unclear 
whether HLA-DR upregulation in tumors precedes or is a 
result of tumor infiltration by immune cells. It is hypoth-
esized that early infiltrating mononuclear cells produce 
IFN-γ and other inflammatory molecules, which drive 
HLA-DR upregulation and further amplify the immune 
response via subsequent activation of effector T cells [12, 
25, 26].
In this study, we determined the level of HLA-DR 
expressed in esophageal tissue compartments at different 
stages in the inflammation to cancer progression sequence, 




Full ethical approval was granted by the St. James’s, Ade-
laide and Meath Hospital, Dublin (SJH/AMNCH) ethics 
committee and the Beaumont Hospital Ethics Board. This 
study was carried out in accordance with the Declaration 
of Helsinki ethical principles for medical research involv-
ing human subjects.
Tissue microarray construction
Three sets of TMA were constructed for this study from 
paraffin-embedded tissue blocks, with pathological exper-
tise from consultant pathologists (Dr.  Brendan Doyle, 
Professor Elaine Kay). TMA set 1 consists of tissue cores 
taken from a cohort of patients with normal squamous 
epithelium (n = 15), esophagitis (n = 32), BE intestinal 
metaplasia (n = 36), LGD (n = 16), HGD (n = 9), and EAC 
(n = 7). TMA set 2 included tissue cores from EAC patients 
where tumor, BE lesions and matched normal mucosa were 
present in resected tissue (n = 29) in patients undergoing 
esophagectomy at Beaumont Hospital, Dublin. TMA set 
3 included tissues from 70 EAC patients undergoing sur-
gical resection at St James’s Hospital, using tissue from 
both tumor core (n = 70) and leading edge tissue (n = 41). 
Areas of interest were marked by a pathologist and 0.6 or 
1  mm cores were taken from the blocks and TMA were 
constructed. Several representative cores (mean n = 2, 
range 1–6) were taken from diagnostic biopsies to construct 
the TMA. 4 μm sections were placed onto Superfrost Plus 
poly-L-lysine coated glass slides (Thermo Fisher Scientific, 
IL, USA), and baked overnight at 37 °C in a tissue drying 
oven (Binder, Tuttlingen, Germany).
Immunohistochemistry
Antigen retrieval was carried out using  Triology™ (Cell 
 Marque™ Corporation, CA, USA), combining three 
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pre-treatment steps: deparaffinization, rehydration and 
unmasking. Sections were incubated in diluted  Triology™ 
(1:20) in a DYB350 programmable pressure cooker on low 
pressure for 10  min. Vectastain Elite kits (Vector Labs, 
CA, USA) were used for all immunohistochemical stain-
ing. Tissue sections were incubated in 3%  H2O2 in metha-
nol (Sigma–Aldrich, MO, USA) to quench endogenous 
peroxidase activity. Sections were washed three times in 
PBS and blocked with normal serum. Sections were stained 
using a 1:1000 dilution of HLA-DR (clone TAL 1B5, 
Abcam, Cambridge, UK) primary antibody. Sections were 
washed three times and incubated in a 1:400 dilution of 
biotinylated secondary antibody, then washed again. Sec-
tions were incubated with avidin–biotin complex reagent, 
followed by washing and incubation with diaminobenzi-
dine (DAB) peroxidase solution (Sigma–Aldrich). Sections 
were rinsed and counterstained in Harris’s haematoxylin 
(Sigma–Aldrich). Sections were dipped in two separate 
baths of 100% methanol (Sigma–Aldrich), transferred into 
two separate baths of xylene (Sigma–Aldrich), before 
being placed in a bath of xylene overnight. Coverslips 
were mounted using DPX mountant (BDH Ltd., Dorset, 
UK). Images were taken using Aperio Scanscope XT digi-
tal scanner. Immunohistochemical staining was assessed 
at 40× magnification in a semi-quantitative manner by 
two independent observers (Dr.  Adriana Michielsen and 
Dr.  Katie O’Sullivan) who were blinded to the pathology 
and  clinical outcome data  during scoring. Epithelial and 
stromal tissue compartments were separately assessed for 
percentage positive staining. A 50% cut-off value was cho-
sen to define HLA-DR high and low staining levels, based 
on the median percentage staining observed.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 
version 5.0 for Windows (GraphPad software, La Jolla, 
CA). One-way ANOVA was used to compare HLA-DR 
expression between groups, and Tukey’s Multiple Com-
parison Test was used to define significantly differing 
groups. Cox proportional hazard regression was used to 
assess the influence of HLA-DR expression on patient sur-
vival. A p value of <0.05 was considered to be significant. 
Kaplan–Meier survival curves were drawn for categorical 
factors and used, along with Schoenfeld residual plots, to 
verify the proportional hazards assumptions made. Sur-
vival was calculated as the time, in months, from the day of 
diagnosis until death of the patient. The last follow-up date 
were used as a cut-off time point for survival calculations.
For multivariate analysis, data were analyzed using 
SPSS version 20.0 (IBM, Armonk, New York, USA). 
Kaplan–Meier estimates were used to calculate survival 
curves, differences in survival curves were calculated using 
log-rank analysis. Cox regression multivariate analysis 
was used to determine independent predictors of survival; 
only variables with significance on univariate analysis were 
input into the multivariate analysis. Statistical significance 
was defined by p value < 0.05.
Results
HLA-DR is upregulated early in the inflammation 
to cancer progression sequence
Figure  1 shows the percentage of HLA-DR positive cells 
present in the esophageal epithelium and stroma cell com-
partments in the cancer progression sequence from nor-
mal esophagus, esophagitis, BE, LGD, HGD to EAC 
tumor. HLA-DR expression in the esophageal epithelium 
is increased in inflammatory states and early dysplasia, but 
levels remain unchanged upon progression from inflam-
mation to cancer (Fig. 1a). This increase was significant in 
patients with BE (p < 0.01) or LGD (p < 0.05), compared 
to normal squamous epithelium. In esophageal stromal tis-
sue (Fig. 1b), HLA-DR expression is significantly elevated, 
at every stage of the progression sequence; esophagi-
tis (p < 0.05), BE (p < 0.001), LGD (p < 0.001), HGD 
(p < 0.01) and EAC (p < 0.01) compared to normal tissue. 
In both epithelial and stromal tissue compartments, HLA-
DR was upregulated at an early, inflammatory stage and 
levels remained high during the progression to cancer.
HLA-DR expression is highest in EAC tumor compared 
to matched BE or adjacent normal tissues
For a more in-depth assessment of tissue-specific HLA-
DR expression, TMA were also constructed from tissue 
samples from 29 resected EAC tumor cases with matched 
BE lesions and normal adjacent tissues, shown in Fig.  2. 
HLA-DR expression in the esophageal epithelium (Fig. 2a) 
was evident in adjacent histologically normal tissue (mean 
percentage positivity 15.3%, range 6.7–42.5%) and was 
significantly increased in matched BE (mean 30%, range 
0–93.3%, p < 0.05) and EAC tissues (mean 34.7%, range 
0–85%, p < 0.01). HLA-DR expression in esophageal tis-
sue stroma (Fig. 2b) followed a similar trend with increas-
ing positivity; although this increase was only significant 
for EAC tissues (mean 27.5%, range 0–56.3%, p < 0.01) 
compared to normal adjacent tissue (mean 17.1%, range 
5–46.3%), but was not significantly altered when compared 
to BE lesions (mean 22%, range 10–44.3%). No significant 
differences in HLA-DR expression were observed when BE 
lesions were compared to EAC tumors, for either the epi-
thelium or stromal compartment.
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EAC patients with a history of BE have higher levels 
of HLA-DR expression in EAC tumor epithelium
HLA-DR expression was compared in EAC patients with 
a history of BE (n = 35) versus those with no known his-
tory of BE (n = 35). HLA-DR expression was significantly 
elevated (p < 0.05) in the EAC tumor epithelium of patients 
with a history of BE (Fig. 3a). No difference was observed 
in EAC stroma (Fig. 3b).
Overall HLA-DR expression pattern is similar 
between EAC tumor core and leading edge tissues, 
but higher in tumor epithelium compared to stroma
Attempts to critically evaluate immune scoring meth-
ods used to predict patient prognosis have highlighted the 
potential for differences in immune scores in different parts 
of tumor tissue. Galon et al., recommend scoring both the 
tumor core and invasive margin [9]. We compared HLA-
DR expression in the EAC tumor core (n = 70) and leading 
Fig. 1  HLA-DR expression is upregulated in esophageal tissue 
early in the inflammation to cancer progression sequence. HLA-DR 
is expressed as percentage positive staining in the epithelium (a) 
and stroma (b) of normal squamous esophageal tissue from healthy 
donors (n = 15), esophagitis patients (n = 32), BE intestinal metapla-
sia (n = 36), LGD (n = 16), HGD (n = 9) and EAC (n = 7) patients. 
One-way ANOVA was used to compare HLA-DR expression between 
groups, and Tukey’s Multiple comparison test was used to define 
significant differences. Representative HLA-DR staining is shown 
for esophageal tissue TMA at various stages in cancer progression 
sequence (C). *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 2  HLA-DR expression is highest in EAC tumor compared to BE 
or normal tissues from the same donor. HLA-DR percentage positive 
staining is shown for esophageal tissue epithelium (a) and stroma (b) 
at different tissue sites from the same EAC donors (n = 29). Repre-
sentative HLA-DR staining is shown for esophageal tissue TMA at 
different sites for a single donor (c). A repeated measures ANOVA 
was used to compare HLA-DR expression between groups, and Tuk-
ey’s Multiple comparison test was used to define statistically different 
groups. *p < 0.05, **p < 0.01
Fig. 3  Patients with a history of BE show higher HLA-DR expres-
sion in EAC tumor epithelium, when compared to EAC patients with 
no known history. HLA-DR expression was significantly elevated in 
tumor epithelium (a) of EAC patients with a history of BE (n = 35), 
compared to EAC patients with no known BE history (n = 35), but not 
in stroma (b). Differences were assessed by t test, *p < 0.05
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edge (n = 41) tissue and found no significant difference in 
the expression pattern between these different sites, either 
in tumor epithelium, or stroma (Fig. 4). HLA-DR was more 
commonly expressed in the EAC tumor epithelium com-
pared to  stroma at both the leading edge (p = 0.0115) and 
tumor core (p = 0.0012), however.
Elevated HLA-DR expression in EAC tumor core 
epithelium strongly correlates with improved patient 
survival
To assess whether HLA-DR expression predicts patient 
survival the setting of EAC, we assessed a cohort of n = 70 
EAC patients (see Supplementary Table  1 for patient 
demographics). Expression was divided into two levels: 
low HLA-DR expression (defined as 0–49% positive stain-
ing) and high HLA-DR expression (defined as 50–100%) 
and Kaplan–Meier survival analysis was performed for 
both cohorts. As shown in Fig. 5, patients with low HLA-
DR expression in the EAC tumor epithelium had a signifi-
cantly shorter survival time compared to patients with high 
expression, in both EAC tumor core (Fig.  5b, p = 0.024, 
HR = 2.18) and leading edge tissue (Fig.  5c, p = 0.013, 
HR = 2.86), upon survival analysis. This survival difference 
was only evident in the EAC tumor epithelium, however, 
and was not observed in EAC tumor stroma (Supplemen-
tary Fig. 1).
In the tumor leading edge epithelium in particu-
lar, low HLA-DR expression was associated with a sig-
nificantly shorter survival (mean 29.8  months, 95% 
CI, range 17.5–42.2  months) than patients with high 
HLA-DR expression (mean 43.4  months, 95% CI, range 
34.0–52.8  months), (p = 0.013). Furthermore, Cox regres-
sion multivariate analysis demonstrated that low HLA-DR 
expression in leading edge epithelium was the single inde-
pendent predictor of poor survival, associated with a 2.8-
fold increase in disease-associated death (p = 0.023), as 
shown in Table 1.
Discussion
The presence of functional antigen presentation machin-
ery is of utmost importance in raising an effective immune 
response against malignancy. The absence or loss of anti-
gen-presenting molecules confers a level of immunological 
invisibility upon tumor cells, and is associated with tumor 
progression, metastasis and poor prognosis [27, 28]. Eleva-
tion of  CD14+HLA-DR−/low cells has been described as an 
indicator of poor prognosis, in terms of patient survival 
[29], increased metastasis and poor response to chemother-
apy [30], whereas elevation of HLA-DR in tumors has been 
associated with favorable outcomes in several cancer types 
[17, 19, 20]. We describe here for the first time that elevated 
HLA-DR expression in tumor epithelium is an independent 
prognostic marker of patient survival in EAC. This obser-
vation agrees with reports in other gastrointestinal cancers 
such as colorectal cancer [16, 18] and gastric cancer [19] 
which also show an association between elevated HLA-DR 
expression in tumors and favorable clinical outcomes.
The association between HLA-DR expression and pro-
longed survival is not true for all types of cancer however 
[15], with elevated HLA-DR even reported as a nega-
tive prognostic marker for certain cancer types, such as 
glioma [21]. The reasons for this discrepancy are unclear 
but could be tissue or cancer type-specific, or alternatively, 
could potentially be attributable to the types of HLA-DR-
expressing cells measured in the tumor microenvironment, 
i.e., tumor epithelial cells as opposed to tumor stromal or 
infiltrating immune cells. Interestingly, we only observed a 
positive prognostic correlation when patient survival was 
measured against HLA-DR expression in the tumor epithe-
lium, but not in the tumor stroma. This difference in tissue 
compartments could potentially explain why other studies, 
which reported a single overall tumor tissue score, failed to 
show a significant correlation between HLA-DR expression 
and patient outcome.
In our multivariate analysis, HLA-DR expression 
in the EAC tumor leading edge was the sole independ-
ent prognostic marker of patient survival. Lymph node 
positivity was significant in univariate (p = 0.001), but 
not multivariate analysis (p = 0.059), unlike other studies 
where lymph node positivity is the single most important 
Fig. 4  Overall HLA-DR expression pattern is similar between EAC 
tumor core and leading edge tissues, but is higher in tumor epithelium 
compared to stroma. HLA-DR percentage positive cells were com-
pared across TMA prepared from EAC tumor core (n = 70) or leading 
edge (n = 41) tissue. HLA-DR expression level was also compared as 
a percentage of positive epithelial cells compared to percentage posi-
tive stroma, in each tissue location. Differences in expression levels 
in different compartments were assessed by Mann–Whitney U test. 
*p < 0.05, **p < 0.01
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prognostic factor [31]. This disparity is most likely due to 
the relatively small number of patients assessed (n = 70). 
In colorectal cancer, Sconocchia and colleagues report a 
significant association between low MHC class II expres-
sion in tumors and lymph node involvement (p < 0.0001) 
[16]. However, whether the prognostic potential of HLA-
DR truly is superior to that of nodal status must be evalu-
ated in a larger patient cohort.
The observation that HLA-DR expression level is only 
prognostically favorable when measured in EAC tumor epi-
thelial cells suggests an intriguing possibility that tumor 
epithelial cells may be performing some immunostimula-
tory function. Indeed, esophageal epithelial cells express-
ing HLA-DR have been shown to have functional ability 
and can effectively process and present antigens to T cells 
[12]. Therefore, it is possible that HLA-DR upregulation 
by tumor epithelial cells plays a direct functional role in 
anti-tumor immunity, potentially acting as a compensatory 
mechanism for tumor-induced inhibition of professional 
antigen-presenting cells such as dendritic cells, as previ-
ously shown by our group in colorectal cancer [32].
Fig. 5  Low HLA-DR expression in EAC tumor epithelium is associ-
ated with worse overall survival. Representative HLA-DR staining is 
shown for TMA constructed from EAC patient tumours (a). Patients 
with low (<50%+) HLA-DR expression in the EAC tumor epithe-
lium were more than twice as likely to die than those patients with 
high (≥50%) expression, as represented by a Kaplan–Meier survival 
curves, in both the tumor core, n = 70 (b) and leading edge, n = 41 (c). 
Associations were tested using a Log-rank (Mantel-Cox) test
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Characterization of HLA-DR expression level across the 
cancer progression sequence shows that HLA-DR upregu-
lation is an early event in inflammation leading to cancer. 
HLA-DR upregulation in inflammation has been previously 
reported in ulcerative colitis [11] and esophagitis [12]. This 
observation is consistent with the hypothesis that HLA-DR 
upregulation occurs in response to various pro-inflamma-
tory mediators, such as IFN-γ [13, 33]. In the esophagus, T 
cells have been implicated in the initiation of inflammation, 
and likely supply these early pro-inflammatory signals [34].
We observed that HLA-DR expression was highest in 
EAC tumor tissues, when compared to matched inflamed 
BE lesions or histologically normal adjacent tissue. This 
was especially true in EAC tumors expressing high (≥50% 
positive) levels of HLA-DR, all of which showed HLA-DR 
expression to be highest in the tumor tissue. This finding 
is similar to observations in colorectal tumors, where both 
percentage of HLA-DR+ cells and staining intensity were 
highest in tumors compared to colorectal adenomas [16].
Differences have been reported in basal HLA-DR 
expression level in different areas of the gastrointestinal 
tract, with small intestinal tissues showing some expres-
sion under normal conditions, whereas colorectal tissues 
typically do not [11, 35]. Reports of HLA-DR expression 
level in tissues varies widely, partially due to inherent vari-
ability in immunohistochemistry methodology and scoring 
methods. However, we observed clear differences in overall 
HLA-DR expression level between EAC tumors and colo-
rectal tumor tissue (data not shown), stained using identi-
cal protocols. Whereas all but one EAC tumor specimen 
stained positively for HLA-DR expression, over half of all 
colorectal tumors scored 0% expression (our unpublished 
observations). Such variable HLA-DR expression patterns 
in different tumor types have been noted in other studies, 
where expression was reported on 12% (n = 8/69) of squa-
mous cell carcinomas of the larynx [20], 67% (n = 47/70) 
gastric carcinomas [19], 22% (n = 13/60) non small cell 
lung cancer cells [36], and 45% (n = 49/108) esophageal 
squamous cell carcinomas [22].
Aside from survival, HLA-DR expression level in the 
tumor core (n = 70) was not significantly associated with 
changes in other clinical parameters tested (Supplementary 
Fig.  2), such as pathological tumor stage (T1–T4) (Sup-
plementary Fig. 2a and b), even when high (T3/T4) versus 
low (T1-T2) stages were grouped for comparison (data not 
shown). Similarly, HLA-DR expression levels were not 
significantly altered when EAC patients were segregated 
by tumor differentiation status (Supplementary Fig.  2  c 
and d), lymph node positivity (Supplementary Fig. 2e and 
f), perineural involvement (data not shown) or overall T 
stage (data not shown). Similar results were observed in 
EAC tumor leading edge tissue (n = 41, data not shown). In 
terms of future work, it will be of great interest to deter-
mine whether HLA-DR expression is associated with EAC 
patient response to neoadjuvant therapy. Multi-modal neo-
adjuvant therapy is rapidly becoming the standard treatment 
option for EAC patients, yet only a minority of patients will 
respond, meaning the majority of patients undergo this 
treatment and its associated side effects without benefit. 
Investigating the immunological basis of this response to 
treatment will be critical in advancing the understanding 
and potential future manipulation of immune responses to 
eliminate established tumors.
In summary, we show that high HLA-DR expression 
in the EAC tumor epithelium is an independent favorable 
prognostic indicator of prolonged patient survival, and 
screening for HLA-DR may be a useful addition to the 
growing number of prognostic immune-based tests.
Table 1  Univariate and 
multivariate analysis examining 
poor predictors of patient 
survival
Univariate analysis p value Multivariate 
analysis p 
value
Female sex 0.058 –
Normal BMI (18.5–24.9) 0.003 0.077
History of BE 0.102 –
Lymphatic invasion 0.044 0.458
Vascular invasion 0.078 –
Perineural invasion 0.105 –
Differentiation 0.079 –
pT stage 0.224 –
pN positivity 0.001 0.059
Low HLA-DR core stroma, n = 70 0.08 –
Low HLA-DR core epithelium, n = 70 0.013 0.106
Low HLA-DR leading edge stroma, n = 41 0.148 –
Low HLA-DR leading edge epithelium, n = 41 0.013 0.023
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